Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Stock Short Interest Declines 78.4%

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a significant drop in short interest in October. As of October 15th, there was short interest totaling 3,004 shares, a drop of 78.4% from the September 30th total of 13,919 shares. Based on an average daily volume of 19,959 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Emmaus Life Sciences Trading Down 13.0%

OTCMKTS EMMA opened at $0.04 on Wednesday. The company has a 50 day moving average price of $0.06 and a 200 day moving average price of $0.02. Emmaus Life Sciences has a 52 week low of $0.01 and a 52 week high of $0.09.

Emmaus Life Sciences (OTCMKTS:EMMA) last issued its quarterly earnings data on Friday, August 14th. The company reported $0.02 EPS for the quarter. The business had revenue of $6.32 million for the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older.

Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.